Your English writing platform
Free sign upSuggestions(5)
Exact(11)
It is important to identify these factors to recognize patients who will benefit from early aggressive therapy and closer monitoring.
In the future, it may be revealed that only patients at high risk have real benefit from early aggressive therapy, but the same approach may result in harm to patients at low risk.
Our findings thus highlight PDUS as a possible surrogate marker of Th17 cells, and may identify patients who would benefit from early, aggressive therapy, including IL-17 antagonists.
Therefore, together several strands of evidence suggest benefit from early, aggressive therapy for pJIA.
Notwithstanding these issues, there are specific populations that would clearly benefit from early, aggressive, and targeted introduction of insulin therapy.
Patients with rapidly progressing joint damage may particularly benefit from early aggressive treatment with a biologic agent.
Similar(49)
Some immunohistological features have been described that distinguish patients who are likely to develop progressive RA and who might benefit most from early aggressive therapeutic intervention.
The overwhelming need in this disease is to diagnose it early and identify those patients who will benefit most from early, aggressive treatment that potentially can alter the clinical disease course.
Moreover, patients at high risk, such as elderly people, may derive maximal benefit from an early aggressive treatment strategy.
The first group can benefit from early and aggressive interventions, which have demonstrated secondary prevention of microvascular and macrovascular complications (10– 10).
The development of such a test may improve the outcome of treatment as high-risk patients could benefit from early intervention and aggressive treatment.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.
Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com